Dilated Cardiomyopathy Clinical Trial
Official title:
Intramyocardial Delivery of Autologous Bone Marrow Cells in Patients With Heart Failure Due to Dilated Cardiomyopathy
This study is designed to assess the safety and tolerability of Cardiac Repair Cells (CRCs) compared to standard-of-care in patients with dilated cardiomyopathy (DCM).
Heart failure remains a major public health problem, affecting 5 million patients in the US with 550,000 new diagnoses made each year. Heart failure is the leading cause of hospitalization in persons over 65 years of age with cost exceeding $29 billion annually. Prognosis is very poor once a patient has been hospitalized with heart failure. The mortality risk after heart failure hospitalization is 11.3% at 30 days, 33.1% at 1 year and well over 50% within 5 years (Hunt SA; et al., 2005). These numbers emphasize the need to develop and implement more effective treatments to manage heart failure. This study is targeting a subset of heart failure patient population, namely those diagnosed with dilated cardiomyopathy (DCM). The World Health Organization (WHO) defines dilated cardiomyopathy as a cardiac condition wherein a ventricular chamber exhibits increased diastolic and systolic volume and a low (<40%) ejection fraction. DCM is reported to affect 108,000 to 150,000 patients in the U.S. This study is a prospective, stratified, randomized, open-label, controlled, multi-center study to assess the safety profile and efficacy of CRCs in treating patients with DCM. It will enroll a total of 40 patients at 5 sites in the U.S. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|
||
Recruiting |
NCT04982081 -
Treating Congestive HF With hiPSC-CMs Through Endocardial Injection
|
Phase 1 | |
Not yet recruiting |
NCT04703751 -
Evaluation of the CIRCULATE Catheter for Transcoronary Administration of Pharmacologic and Cell-based Agents
|
N/A | |
Recruiting |
NCT01157299 -
Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO
|
N/A | |
Completed |
NCT02115581 -
Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy
|
Phase 4 | |
Recruiting |
NCT04246450 -
Arrhythmic Risk Stratification in Nonischemic Dilated Cardiomyopathy
|
N/A | |
Recruiting |
NCT05799833 -
Low QRS Voltages in Young Healthy Individuals and Athletes
|
||
Recruiting |
NCT01914081 -
Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside
|
Phase 3 | |
Recruiting |
NCT02915718 -
A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy
|
N/A | |
Recruiting |
NCT03061994 -
Metabolomic Study of All-age Cardiomyopathy
|
N/A | |
Completed |
NCT03893760 -
Assessment of Right Ventricular Function in Advanced Heart Failure
|
||
Not yet recruiting |
NCT01219452 -
Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT02175836 -
Arrhythmia Prediction Trial
|
N/A | |
Active, not recruiting |
NCT00962364 -
Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease
|
||
Recruiting |
NCT05026112 -
The Arrhythmogenic Potential of Midwall Septal Fibrosis in Dilated Cardiomyopathy
|
||
Recruiting |
NCT05237323 -
Micophenolate Mofetil Versus Azathioprine in Myocarditis
|
Phase 3 | |
Recruiting |
NCT04649034 -
Intraventricular Stasis In Cardiovascular Disease
|
||
Suspended |
NCT03071653 -
Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study
|
Phase 2 | |
Completed |
NCT02619825 -
Non-Invasive Evaluation of Myocardial Stiffness by Elastography in Pediatric Cardiology (Elasto-Pédiatrie)
|
N/A | |
Recruiting |
NCT02989181 -
Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea
|
Phase 3 |